BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Clinical strategy at BIO‑Europe 2026

Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website

39 organizations at BIO-Europe 2026 present work in clinical strategy: 24 service providers, 12 drug developers, 2 investors and 1 academic, government or non-profit body. Between them they bring 55 presentations to the program. Most represented: Bayer (6 on the program), Biogen (4 on the program), Miltenyi Biomedicine (3 on the program). As of Nov 10, 2026.

All 473 organizations at BIO-Europe 2026 →

Format
Top represented
Showing 1–14 of 39 organizations
OrganizationBIO-Europe 2026 Attendance
Bayer
Leverkusen, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Life sciences company with pharmaceuticals, consumer health and crop science divisions.
Talk
Tue Nov 10
09:00–09:30
An Outlook into the Year 2050: Navigating the Future of Efficiency and Innovation
How AI, global expansion and patient community outreach may reshape the way clinical trials are run, and what to change now to prepare.
Panel
Tue Nov 10
15:00–15:25
Inside the Incubator: What It Really Takes to Build a Biotech Company Today
What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners.
with Phinomics
Panel
Tue Nov 10
16:30–16:55
The Role of Innovation in Biopharma Growth
How new ideas and technologies drive growth for drug companies, and how to keep innovating while scaling up, with real examples.
Panel
Wed Nov 11
10:00–10:45
AI Regulations: Driving Innovation While Navigating Compliance
What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation.
with European Medicines Agency
Panel
Wed Nov 11
11:00–12:00
Collaborative Innovation in CDMO Partnerships
How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle.
with Eleva, Evotec
Biogen
Cambridge, Massachusetts
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Develops and markets therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's disease.
Talk
Mon Nov 9
09:00–10:00
Build, Buy, or Partner? Choosing Your Market Entry Strategy
How drug companies choose between licensing a new product to a regional partner, selling it themselves, or both, with lessons from each path.
with Blue Matter Consulting, Idorsia, Protagonist Therapeutics
Business of Biotech
Panel
Mon Nov 9
13:00–14:00
Navigating partnering and business development in a shifting global landscape
How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples.
with Syneos Health, Genmab, Astellas +2 more
Panel
Tue Nov 10
16:00–16:45
AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development
How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed.
with PharmSky Research, TransPerfect, Atrogi
Panel
Tue Nov 10
15:00–15:45
Mastering the Shifting Regulatory Landscape: Leveraging the Biotech Act for Innovation and Global Success
How the EU Biotech Act aims to restore Europe's edge through faster trial approvals, quicker rare disease access and proportionate oversight of advanced therapies.
with Roche
Miltenyi Biomedicine
Bergisch Gladbach, Germany
Biotech
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease.
Panel
Tue Nov 10
10:00–10:45
Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making
How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner.
with IGES Institut, Krystal Biotech, EFPIA +1 more
Panel
Tue Nov 10
09:30–09:55
From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients
Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials.
Talk
Wed Nov 11
09:30–09:55
Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies
How cell therapies built for cancer are moving into autoimmune disease, and how trial endpoints, risk expectations and teams must change.
Consulting, legal & services
Regulatory consultancy advising drug developers on regulatory and commercialization pathways, including gene therapy applications.
Panel
Mon Nov 9
14:00–14:45
Community Conversations – Session 1
Attendees join small-group lunch tables on a topic of their choice, from regulatory strategy and global launches to hiring talent and managing partnerships.
with R Kupiec Consulting, Sartorius, Venture Valuation +3 more
Business of BiotechRegulatory Strategy
Panel
Mon Nov 9
15:00–15:45
Community Conversations – Session 2
A second round of the same small-group lunch tables, letting attendees switch to another topic such as regulatory strategy, launches or partnerships.
with R Kupiec Consulting, Sartorius, Venture Valuation +3 more
Business of BiotechRegulatory Strategy
Panel
Tue Nov 10
13:00–13:55
Unlocking APACs Clinical Trials Potential: Navigating Regulatory Pathways, Bridging Strategies and Market Access Across the Region
How to run clinical trials and win approval in Japan, Korea, Taiwan and Southeast Asia, and when studies in local patients pay off.
with HiRO, CMIC Group, Differentia Bio
Parexel
Durham, NC
◆Platinum Sponsor
CDMO & CROPlatinum sponsor
Clinical research organization providing clinical development, regulatory consulting and market access services to biopharmaceutical companies.
Panel
Tue Nov 10
14:00–14:25
Navigating the Evolving Regulatory Landscape: Strategies for Clinical Success in an Era of Transformation
How rare disease drugs can win approval with few patients, how FDA leadership changes shift priorities, and how real-world data can strengthen applications.
with AOP Health
Panel
Tue Nov 10
16:00–16:45
Unlocking Clinical Trial Systems
How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely.
with R Kupiec Consulting, Merck KGaA, AstraZeneca
A
Atrogi
Stockholm, Sweden
Biotech
Develops oral small molecules for type 2 diabetes and obesity that increase glucose uptake in skeletal muscle.
Panel
Tue Nov 10
16:00–16:45
AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development
How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed.
with PharmSky Research, TransPerfect, Biogen
Panel
Tue Nov 10
10:00–10:45
Cardiometabolic innovations beyond GLP-1 – Where are we now?
Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going.
with LifeArc, IsomAb, V-Bio Ventures +2 more
Consulting, legal & services
Australian not-for-profit organization providing human research ethics committee review for clinical trials and other health research.
Panel
Wed Nov 11
09:55–10:25
What Starts Down Under Doesn’t Stay Down Under: Australian Clinical Data as a Global Launchpad
How companies use clinical data gathered in Australia to move into multinational trials, raise investment and launch products worldwide.
with Alithia Life Sciences, Crux Biolabs, CMAX Clinical Research +1 more
CDMO & CRO
Not-for-profit first-in-human Phase 1 clinical trial unit in the Randwick health precinct, also running later-phase oncology and haematology trials.
Panel
Tue Nov 10
14:30–15:00
Accelerating First-in-Human: Why Australia is the Fast Track to the Clinic
Why Australia suits a drug's first trials in people, with supportive rules, engaged doctors and data that European and US regulators accept.
with MaH Clinical Trial Solutions, Agilex Biolabs, BioCina +1 more
Biotech
Develops oral small-molecule allosteric inhibitors for chronic inflammation, fibrosis and cancer, led by an oral inhibitor of IL-1β production.
Panel
Wed Nov 11
10:30–10:55
Building a Clinical Strategy for Rare Disease Therapeutics
How bold trial designs, such as adaptive trials and basket trials testing one drug in several diseases, can help a first-of-its-kind therapy succeed.
with Gibela Therapeutics, Cellula Therapeutics
Panel
Wed Nov 11
09:00–09:25
Learning from Failures and Successes in Clinical Trials
What failed and successful clinical trials teach about designing and running better trials, using real examples.
with Cereno Scientific, Digital Medicine Society (DiMe)
CT
Cellula Therapeutics
Epalinges, Switzerland
Biotech
Swiss cell therapy biotech spun out of the University of Geneva.
Panel
Wed Nov 11
10:30–10:55
Building a Clinical Strategy for Rare Disease Therapeutics
How bold trial designs, such as adaptive trials and basket trials testing one drug in several diseases, can help a first-of-its-kind therapy succeed.
with Allinky Biopharma, Gibela Therapeutics
Panel
Wed Nov 11
11:00–11:45
Capital with a Mission: Investing Beyond Traditional Venture Models
How mission-driven and foundation investors fund neglected diseases such as glioblastoma and neuroblastoma that venture capital passes over, focusing on Switzerland.
with Remora Biotech, Ampleia, Argobio
Consulting, legal & services
Consultancy advising pharma, medtech and digital health companies on China-Europe policy, regulation, market access and expansion.
Talk
Tue Nov 10
09:30–09:45
Before the Deal: What Western Buyers Must Resolve About China-Origin Evidence and Policy Risk
What Western buyers should check before buying rights to a China-developed drug, from whether its trial data satisfy European regulators to political risk.
Panel
Tue Nov 10
09:45–10:45
China’s Clinical Revolution: From Regional Player to Global Innovation Engine
Why global drug companies license more drugs from Chinese biotechs, and how China's fast trials and changing rules can speed worldwide development.
with Tigermed, MSQ Ventures, Alkeus Pharmaceuticals
◆Platinum Sponsor
Tools, data & AIPlatinum sponsor
AI company offering AI-powered clinical development services and software, from protocol design and data management to regulatory documents.
Talk
Mon Nov 9
09:00–10:00
Doctor-to-Doctor: A PI-Led Pathway into Japan Using AI, DCT, and Registration-Directed Investigator-Initiated Trials to Reach Japanese Patients Faster
How trials led by the right Japanese doctor, rather than a contract research company, can take a drug toward approval in Japan.
Clinical StrategyRegulatory Strategy
◇Silver Sponsor
Tools, data & AISilver sponsor
Clinical trial planning software and data covering patient, country and site feasibility, for pharma and biotech companies and contract research organizations.
Panel
Tue Nov 10
15:00–15:25
Expanding Global Clinical Trials: Opportunities and Challenges in Emerging Markets
How to expand clinical trials into emerging markets and underserved groups, from picking contract research companies and sites to building local partnerships.
AB
Agilex Biolabs
Adelaide, Australia
CDMO & CRO
Australian bioanalytical laboratory providing regulated bioanalysis, toxicology and immunology testing for clinical trials.
Panel
Tue Nov 10
14:30–15:00
Accelerating First-in-Human: Why Australia is the Fast Track to the Clinic
Why Australia suits a drug's first trials in people, with supportive rules, engaged doctors and data that European and US regulators accept.
with Scientia Clinical Research, MaH Clinical Trial Solutions, BioCina +1 more

Explore the full BIO-Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Cologne. Leave your work email and we’ll be in touch.

Privacy

Download the full BIO-Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in clinical strategy

Tell us what you sell and we’ll find the people at organizations working on clinical strategy most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse BIO-Europe 2026 by

Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction